Psychedelic and ketamine research trials in Australia
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
12 registered studies are counted in Australia. By compound: 4 psilocybin, 1 MDMA, 6 ketamine and 1 ibogaine. By registry status: 3 recruiting, 1 not yet recruiting, 5 completed and 3 status not reported. By phase: 5 phase 1, 4 phase 2 and 3 phase 4. Reported start years run from 2008 (earliest) to 2025 (latest). Studies are linked to 10 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
4 of the 12 counted studies are listed in the registry as recruiting (3) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) | NCT07247370 | Not yet recruiting | Phase 1 | 2025-12-10 | South West Sydney Local Health District, Sydney |
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | NCT07072728 | Recruiting | Phase 2 | 2025-10-01 | Psyence Australia Pty Ltd, Abbotsford |
| Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | NCT06278779 | Recruiting | Phase 4 | 2024-06-03 | The George Institute, Camperdown |
| Positioning of Esketamine Treatment in the Real-world Management of Depression | NCT06103760 | Recruiting | Phase 4 | 2023-10-31 | Royal North Shore Hospital, St Leonards |
At a glance
- 12 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| MDMA | 1 |
| Ketamine | 6 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 25% |
| Not yet recruiting | 1 | 8% |
| Completed | 5 | 42% |
| Status not reported | 3 | 25% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 5 | 42% |
| Phase 2 | 4 | 33% |
| Phase 4 | 3 | 25% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 6 |
| 2020 to 2023 | 3 |
| 2015 to 2019 | 1 |
| 2010 to 2014 | 1 |
| Before 2010 | 1 |
All counted studies
All 12 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) | NCT07247370 | Not yet recruiting | Phase 1 | 2025-12-10 | South West Sydney Local Health District, Sydney |
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | NCT07072728 | Recruiting | Phase 2 | 2025-10-01 | Psyence Australia Pty Ltd, Abbotsford |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants | NCT06643637 | Completed | Phase 1 | 2024-11-08 | MycoMedica Life Sciences PBC, Adelaide |
| Psilocybin-assisted Therapy for Alcohol Use Disorder | NCT06444243 | Status not reported | Phase 2 | 2024-09-01 | University of Sydney, Sydney |
| Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | NCT06278779 | Recruiting | Phase 4 | 2024-06-03 | The George Institute, Camperdown |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants | NCT06326606 | Completed | Phase 1 | 2024-03-27 | MycoMedica Life Sciences PBC, Adelaide |
| Positioning of Esketamine Treatment in the Real-world Management of Depression | NCT06103760 | Recruiting | Phase 4 | 2023-10-31 | Royal North Shore Hospital, St Leonards |
| MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder | NCT05709353 | Status not reported | Phase 2 | 2023-09-19 | University of Sydney, Sydney |
| A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers | NCT04292197 | Completed | Phase 1 | 2020-04-14 | Definium Therapeutics US, Inc., Perth |
| Ketamine Trial for the Treatment of Depression | NCT02401139 | Completed | Phase 1 | 2015-03-01 | The University of New South Wales, Camperdown |
| A Study of Ketamine as an Antidepressant | NCT01441505 | Status not reported | Phase 2 | 2011-09-01 | The University of New South Wales, Kogarah |
| Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT) | NCT00680433 | Completed | Phase 4 | 2008-04-01 | Northside Clinic, Australia, Sydney |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine | Ibogaine
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 6 |
| Alcohol use disorder | 3 |
| Anxiety | 2 |
| Cancer and end-of-life distress | 1 |
| Post-traumatic stress disorder | 1 |
| Treatment-resistant depression | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Netherlands | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland